BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ethun CG, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB, Chapman WC, Krasnick BA, Weber SM, Mezrich JD, Salem A, Pawlik TM, Poultsides G, Tran TB, Idrees K, Isom CA, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Cardona K, Maithel SK. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease. Ann Surg. 2018;267:797-805. [PMID: 29064885 DOI: 10.1097/sla.0000000000002574] [Cited by in Crossref: 68] [Cited by in F6Publishing: 33] [Article Influence: 22.7] [Reference Citation Analysis]
Number Citing Articles
1 Tan EK, Taner T, Heimbach JK, Gores GJ, Rosen CB. Liver Transplantation for Peri-hilar Cholangiocarcinoma.J Gastrointest Surg. 2020;24:2679-2685. [PMID: 32671802 DOI: 10.1007/s11605-020-04721-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
2 Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World J Gastroenterol 2020; 26(25): 3542-3561 [PMID: 32742125 DOI: 10.3748/wjg.v26.i25.3542] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
3 Ahmed O, Vachharajani N, Chang SH, Park Y, Khan AS, Chapman WC, Doyle MBM. Single-center experience of liver transplantation for perihilar cholangiocarcinoma. HPB (Oxford) 2021:S1365-182X(21)01584-7. [PMID: 34465528 DOI: 10.1016/j.hpb.2021.08.940] [Reference Citation Analysis]
4 Safarpour AR, Askari H, Ejtehadi F, Azarnezhad A, Raeis-Abdollahi E, Tajbakhsh A, Abazari MF, Tarkesh F, Shamsaeefar A, Niknam R, Sivandzadeh GR, Lankarani KB, Ejtehadi F. Cholangiocarcinoma and liver transplantation: What we know so far? World J Gastrointest Pathophysiol 2021; 12(5): 84-105 [PMID: 34676129 DOI: 10.4291/wjgp.v12.i5.84] [Reference Citation Analysis]
5 Cai Z, Yin Y, Cai Z, Zhao Z, Shen C, Yin X, Wang J, Chen Z, Cao D, Zhang B. Efficacy of liver transplantation for hilar cholangiocarcinoma: A protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e11626. [PMID: 30045305 DOI: 10.1097/MD.0000000000011626] [Reference Citation Analysis]
6 Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557-588. [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z] [Cited by in Crossref: 160] [Cited by in F6Publishing: 167] [Article Influence: 80.0] [Reference Citation Analysis]
7 Petrowsky H, Fritsch R, Guckenberger M, De Oliveira ML, Dutkowski P, Clavien P. Modern therapeutic approaches for the treatment of malignant liver tumours. Nat Rev Gastroenterol Hepatol 2020;17:755-72. [DOI: 10.1038/s41575-020-0314-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
8 Braunwarth E, Stättner S, Fodor M, Cardini B, Resch T, Oberhuber R, Putzer D, Bale R, Maglione M, Margreiter C, Schneeberger S, Öfner D, Primavesi F. Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma. Eur Surg 2018;50:100-12. [PMID: 29875798 DOI: 10.1007/s10353-018-0537-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
9 Panayotova GG, Paterno F, Guarrera JV, Lunsford KE. Liver Transplantation for Cholangiocarcinoma: Insights into the Prognosis and the Evolving Indications. Curr Oncol Rep. 2020;22:49. [PMID: 32297105 DOI: 10.1007/s11912-020-00910-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Saffioti F, Mavroeidis VK. Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. World J Gastrointest Oncol 2021; 13(10): 1336-1366 [PMID: 34721770 DOI: 10.4251/wjgo.v13.i10.1336] [Reference Citation Analysis]
11 Azad AI, Rosen CB, Taner T, Heimbach JK, Gores GJ. Selected Patients with Unresectable Perihilar Cholangiocarcinoma (pCCA) Derive Long-Term Benefit from Liver Transplantation.Cancers (Basel). 2020;12. [PMID: 33121179 DOI: 10.3390/cancers12113157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, Ijzermans JNM, Vivarelli M, Zieniewicz K, Olde Damink SWM, Groot Koerkamp B. Surgery for cholangiocarcinoma. Liver Int 2019;39 Suppl 1:143-55. [PMID: 30843343 DOI: 10.1111/liv.14089] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 20.0] [Reference Citation Analysis]
13 Fong ZV, Brownlee SA, Qadan M, Tanabe KK. The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines. Ann Surg Oncol 2021;28:2660-74. [PMID: 33646431 DOI: 10.1245/s10434-021-09671-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Rep 2019;1:377-91. [PMID: 32039389 DOI: 10.1016/j.jhepr.2019.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
15 Juratli MA, Struecker B, Katou S, Morguel MH, Pascher A. [Influence of molecular pathology on oncological surgery of liver and bile duct tumors]. Chirurg 2021;92:1003-10. [PMID: 34519849 DOI: 10.1007/s00104-021-01495-6] [Reference Citation Analysis]
16 Gringeri E, Gambato M, Sapisochin G, Ivanics T, Lynch EN, Mescoli C, Burra P, Cillo U, Russo FP. Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology. J Clin Med 2020;9:E1353. [PMID: 32380750 DOI: 10.3390/jcm9051353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yilmaz S, Carr BI, Akbulut S. Can the Limits of Liver Transplantation Be Expanded in Perihilar Cholangiocarcinoma? J Gastrointest Cancer 2021. [PMID: 34738188 DOI: 10.1007/s12029-021-00735-6] [Reference Citation Analysis]
18 Li Z, Jiang X, Huang L, Li J, Ji D, Xu Y, Leng K, Cui Y. Up-regulation of ZFAS1 indicates dismal prognosis for cholangiocarcinoma and promotes proliferation and metastasis by modulating USF1 via miR-296-5p. J Cell Mol Med 2019;23:8258-68. [PMID: 31565837 DOI: 10.1111/jcmm.14698] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
19 She WH, Dai WC, Fung JY, Cheung TT, Chan AC, Lo CM. Recurrent pyogenic cholangitis: An indication for liver transplantation. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00178-8. [PMID: 34657803 DOI: 10.1016/j.hbpd.2021.09.008] [Reference Citation Analysis]
20 Benzing C, Krenzien F, Mieg A, Wolfsberger A, Andreou A, Nevermann N, Pelzer U, Fehrenbach U, Haiden LM, Öllinger R, Schöning W, Schmelzle M, Pratschke J. A tailored approach in lymph node-positive perihilar cholangiocarcinoma. Langenbecks Arch Surg 2021;406:1499-509. [PMID: 34075473 DOI: 10.1007/s00423-021-02154-4] [Reference Citation Analysis]
21 Gringeri E, Gambato M, Furlanetto A, Ballo M, Nieddu E, Cillo U. Unchanged surgical management of patients with Cholangiocarcinoma during the COVID-19 pandemic. Dig Liver Dis 2020;52:944-5. [PMID: 32646733 DOI: 10.1016/j.dld.2020.06.033] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Moris D, Kostakis ID, Machairas N, Prodromidou A, Tsilimigras DI, Ravindra KV, Sudan DL, Knechtle SJ, Barbas AS. Comparison between liver transplantation and resection for hilar cholangiocarcinoma: A systematic review and meta-analysis. PLoS One. 2019;14:e0220527. [PMID: 31365594 DOI: 10.1371/journal.pone.0220527] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
23 Nadalin S, Genedy L, Königsrainer A. Liver Living Donation for Cancer Patients: Benefits, Risks, Justification. Recent Results Cancer Res 2021;218:135-48. [PMID: 34019167 DOI: 10.1007/978-3-030-63749-1_10] [Reference Citation Analysis]
24 Soares KC, Jarnagin WR. The Landmark Series: Hilar Cholangiocarcinoma. Ann Surg Oncol 2021;28:4158-70. [PMID: 33829358 DOI: 10.1245/s10434-021-09871-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Mehrotra S, Lalwani S, Nundy S. Management Strategies for Patients with Hilar Cholangiocarcinomas: Challenges and Solutions. Hepat Med 2020;12:1-13. [PMID: 32158282 DOI: 10.2147/HMER.S223022] [Reference Citation Analysis]
26 Manzia TM, Parente A, Lenci I, Sensi B, Milana M, Gazia C, Signorello A, Angelico R, Grassi G, Tisone G, Baiocchi L. Moving forward in the treatment of cholangiocarcinoma. World J Gastrointest Oncol 2021; 13(12): 1939-1955 [DOI: 10.4251/wjgo.v13.i12.1939] [Reference Citation Analysis]
27 Zori AG, Yang D, Draganov PV, Cabrera R. Advances in the management of cholangiocarcinoma. World J Hepatol 2021; 13(9): 1003-1018 [PMID: 34630871 DOI: 10.4254/wjh.v13.i9.1003] [Reference Citation Analysis]
28 Lang SA, Bednarsch J, Czigany Z, Joechle K, Kroh A, Amygdalos I, Strnad P, Bruns T, Heise D, Ulmer F, Neumann UP. Liver transplantation in malignant disease. World J Clin Oncol 2021; 12(8): 623-645 [PMID: 34513597 DOI: 10.5306/wjco.v12.i8.623] [Reference Citation Analysis]
29 Figueiredo C, Oldhafer F, Wittauer EM, Carvalho-Oliveira M, Akhdar A, Beetz O, Chen-Wacker C, Yuzefovych Y, Falk CS, Blasczyk R, Vondran FWR. Silencing of HLA class I on primary human hepatocytes as a novel strategy for reduction in alloreactivity. J Cell Mol Med 2019;23:5705-14. [PMID: 31180181 DOI: 10.1111/jcmm.14484] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
30 Matsukuma S, Tokumitsu Y, Shindo Y, Matsui H, Nagano H. Essential updates to the surgical treatment of biliary tract cancer. Ann Gastroenterol Surg 2019;3:378-89. [PMID: 31346577 DOI: 10.1002/ags3.12266] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
31 Resch T, Esser H, Cardini B, Schaefer B, Zoller H, Schneeberger S. Liver transplantation for hilar cholangiocarcinoma (h-CCA): is it the right time? Transl Gastroenterol Hepatol 2018;3:38. [PMID: 30148223 DOI: 10.21037/tgh.2018.06.06] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Finotti M, Auricchio P, Vitale A, Gringeri E, Cillo U. Liver transplantation for rare liver diseases and rare indications for liver transplant. Transl Gastroenterol Hepatol 2021;6:27. [PMID: 33824931 DOI: 10.21037/tgh-19-282] [Reference Citation Analysis]
33 Yu TN, Mao YY, Wei FQ, Liu H. Cystic duct cancer: Should it be deemed as a type of gallbladder cancer? World J Gastroenterol 2019; 25(44): 6541-6550 [PMID: 31802833 DOI: 10.3748/wjg.v25.i44.6541] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Schmelzle M, Schöning W, Pratschke J. [Surgical treatment of malignant biliary tract diseases]. Chirurg 2020;91:3-10. [PMID: 31701167 DOI: 10.1007/s00104-019-01062-0] [Reference Citation Analysis]
35 Capanu M, Giurcanu M, Begg CB, Gönen M. Optimized variable selection via repeated data splitting. Stat Med 2020;39:2167-84. [PMID: 32282097 DOI: 10.1002/sim.8538] [Reference Citation Analysis]
36 Lauterio A, De Carlis R, Centonze L, Buscemi V, Incarbone N, Vella I, De Carlis L. Current Surgical Management of Peri-Hilar and Intra-Hepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:3657. [PMID: 34359560 DOI: 10.3390/cancers13153657] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Aveson VG, Ilagan CH, Chou JF, Gönen M, Balachandran VP, Drebin JA, Jarnagin WR, Wei AC, Kingham TP, D'Angelica MI. Association between biopsy method and development of peritoneal metastases in perihilar cholangiocarcinoma. HPB (Oxford) 2021:S1365-182X(21)01692-0. [PMID: 34844860 DOI: 10.1016/j.hpb.2021.11.001] [Reference Citation Analysis]
38 Li H, Chen L, Zhu GY, Yao X, Dong R, Guo JH. Interventional Treatment for Cholangiocarcinoma. Front Oncol 2021;11:671327. [PMID: 34268114 DOI: 10.3389/fonc.2021.671327] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Panayotova G, Guerra J, Guarrera JV, Lunsford KE. The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2428. [PMID: 34070772 DOI: 10.3390/jcm10112428] [Reference Citation Analysis]
40 Zhang Y, Wu Z, Wang X, Li C, Chang J, Jiang W, Wang H, Wang Y, Li X. Development and external validation of a nomogram for predicting the effect of tumor size on survival of patients with perihilar cholangiocarcinoma. BMC Cancer 2020;20:1044. [PMID: 33126868 DOI: 10.1186/s12885-020-07501-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Ilyas FZ, Beane JD, Pawlik TM. The State of Immunotherapy in Hepatobiliary Cancers. Cells 2021;10:2096. [PMID: 34440865 DOI: 10.3390/cells10082096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]